At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Timolol Gel +1 moredrug
Likely dose
Timolol Gel 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Timolol Gel and Placebo Gel for Hereditary Hemorrhagic Telangiectasia. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This study is a double-blinded, randomized controlled trial to evaluate the efficacy of an intranasal topical timolol gel in the care for epistaxis in adults with hereditary hemorrhagic telangiectasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Hemorrhagic Telangiectasia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedOct 2019
Primary CompletionMay 2020
TodayJul 2026
First PostedOct 25, 2019
Enrollment StartOct 20, 2019
Primary CompletionMay 20, 2020
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 6.7 years ago
Interventions
Timolol Geldrug
Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
Placebo Geldrug
Placebo gel is prepared with poloxamers and no active ingredients.